130 results about "Phosphodiester alpha" patented technology

Oligomeric compounds (including those that are antisense agents or portions thereof) are provided that comprise a modified oligonucleotide having at least one modified internucleoside linking group.SOLUTION: By an oligomeric compound comprising a modified oligonucleotide consisting of 12 to 70 linked nucleosides linked via internucleoside linking groups, wherein at least one nucleoside comprises a modified sugar moiety and wherein at least one internucleoside linking group is a phosphodiester or phosphorothioate internucleoside linking group.SELECTED DRAWING: Figure 1

The invention relates in general to the field of CAR-T cells. The invention in particular relates to improved methods for obtaining CAR-T cells, and improved CAR-T cells, as well as uses thereof. The method in further relates to activating or expressing a phosphodiesterase (PDE) in T-cells during CAR-T cell generation.

This invention belongs to the field of medicinal chemistry, specifically relating to benzofuran compounds or their pharmaceutically acceptable salts, their preparation methods, and applications. The benzofuran compounds of this invention can significantly inhibit the activity of phosphodiesterase 4 and can be used to prepare drugs for treating inflammatory diseases, autoimmune diseases, or neuropsychiatric disorders, especially for stroke and ischemic dementia-related diseases.

The disclosure relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) useful for the treatment of certain cancers or tumors, such as colon cancer. In another embodiment, the disclosure relates to the use of inhibitors of PDE1 and an optional antitumor agent for the treatment of certain cancers or tumors.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

This invention discloses a genetically engineered bacterium capable of synthesizing large quantities of natural cyclic diguanylate (c-di-GMP) and its applications. It involves knocking out the major phosphodiesterase gene chr1_233 as described in claim 1 within the sphingobium xenophagum C2 strain. This invention rationally designs and modifies the c-di-GMP synthesis and degradation pathways and the inhibitory site of major diguanylate cyclase activity in heterologous sphingobium-consuming bacteria, constructing a series of genetically engineered bacteria capable of synthesizing large quantities of natural c-di-GMP. This provides the industry with a green, simple, economical, and efficient method for producing natural c-di-GMP, and offers a series of high-quality and inexpensive raw materials for the preparation of STING agonists or immune adjuvants, or for the preparation of drugs for treating diseases related to STING protein function.

The invention relates to a process for the production of a mixed P═O / P═S backbone oligonucleotide comprising a selective oxidation of an intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II according to the scheme with an oxidation solution obtained by mixing iodine, an organic solvent and water, characterized in that the oxidation solution has been aged for a time period that is sufficient to selectively oxidize the phosphite triester compound of formula I into the phosphodiester compound of formula II without oxidizing the phosphorothioate internucleotide linkages.

The present disclosure relates generally to processes for providing compounds that can be used as inhibitors of ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1), which inhibitors can be useful in treating or preventing soft bone diseases, such as hypophosphatasia (HPP).

This application relates to a series of novel compounds that are selective inhibitors of phosphodiesterase type 9 ("PDE9") for the treatment of chronic heart failure. More specifically, this application relates to pyrazolo[3,4-d]pyrimidinone compounds for use in the treatment and prevention of chronic heart failure.

To provide small-molecule modulators of ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1).SOLUTION: Provided is a compound having the structure of Formula (I), or a pharmaceutically acceptable salt or solvate thereof: SELECTED DRAWING: None

This specification describes methods for treating cancer using small molecule ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) inhibitors and additional agents.

The invention discloses an application of a novel phosphodiesterase 4 (PDE4) inhibitor ZL-n-91 in preparation of drugs for treating growth and metastasis of small cell lung cancer. In-vitro cytology experiments and in-vivo zoology experiments show that the phosphodiesterase 4 inhibitor ZL-n-91 can significantly inhibit proliferation and metastasis of small cell lung cancer, and the phosphodiesterase 4 inhibitor ZL-n-91 is expected to treat small cell lung cancer and has good development and application prospects.

Provided herein are methods for treating hypophosphoesterase (HPP), the methods comprising administering a therapeutically effective amount of an inhibitor of exonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1).

A method for confirming the sequence of a nucleic acid is provided, comprising: (i) hydrolytic cleavage of predetermined phosphodiester bonds in the nucleic acid to generate a plurality of oligonucleotides; (ii) ionization of the plurality of oligonucleotides to provide a gas phase of ionized oligonucleotides, wherein a majority of the ionized oligonucleotides are singly charged; (iii) isolation of the ionized oligonucleotides using a plurality of mass-to-charge ratio (m / z) windows; (iv) detection of the isolated ionized oligonucleotides of each m / z window using a high-resolution mass spectrometer (HRMS) with a resolution of more than 30.000 at m / z 200, thereby obtaining a mass spectrum; (v) Confirming the sequence of the nucleic acid by comparing the mass spectrum obtained in step (iv) with a mass spectrum determined in silico after the same hydrolytic cleavage of the nucleic acid as in step (i), the confirmation comprising a comparison of the signal intensities of one or more mass envelopes resulting from the ionized oligonucleotides.

The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and / or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and / or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V / VI) and / or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and / or regulated in response to two casein kinase 1 delta inhibitors.

Provided herein are methods of treating Tourette Syndrome in a subject in need thereof by administering to the subject compositions comprising a PDE10 inhibitor. Also disclosed are crystalline solid forms of the compound of Formula I and uses thereof:

The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, including methods of treatment and pharmaceutical compositions for use therein.

The invention relates to the technical field of medicines, in particular to a novel medical application of a phosphodiesterase 4B inhibitor namiklast, and particularly relates to an application of namiklast in preparation of a medicine for treating intervertebral disc fibrosis through targeted inhibition of macrophage-myofibroblast transformation.

The instant invention relates to the use of a substance with phosphodiesterase-7 inhibitory activity (PDE7 inhibitor) as active ingredient in a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of different diseases, syndromes, disease states, or conditions associated with chronic fatigue, exhaustion and / or exertional intolerance using PDE7 inhibitors alone or in combination with other therapeutic agents.

A method of reducing fear memory in a mammal comprising the step of inhibiting or reducing cAMP signaling in the mammal. The cAMP signaling can be reduced using an adenylyl cyclase 1 (AC1) inhibitor or using a phosphodiesterase, such as a cAMP-specific phosphodiesterase, such as PDE4.

The present invention relates to a product for use in the treatment, prevention, or remission of prostate cancer in subjects requiring treatment, prevention, or remission, wherein the product induces the expression of PDE4D7 or promotes the activity of phosphodiesterase 4D7. The product may be a direct or indirect activator of PDE4D7 activity, or a product for causing or promoting the expression of PDE4D7 in a subject. The present invention further specifies kits of elements and the in vitro or ex vivo use of the product.

This invention generally relates to veterinary use of an ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) inhibitor, e.g., for modulating (e.g., inhibiting) ENPP1 activity and / or signaling, for example, for the treatment or prophylaxis of periodontal disease or bone disorder, such as periodontitis.

The present invention provides oligonucleotide and / or oligonucleotide analogue molecules which are antagonists of microRNAs, preferably of human microRNAs hsa-miR-23b-3p and hsa-miR-218-5p, which comprise a mixture of phosphorothioate and phosphodiester linkages, and which are conjugated to at least one oleic acid molecule. Inhibition of these microRNAs can increase the endogenous levels of the corresponding proteins MBNL1 and / or MBNL2. The present invention further provides compositions comprising said oligonucleotide and / or oligonucleotide analogue molecules and their use for the treatment and prevention of diabetes in a subject in need thereof.

A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.

The invention discloses an application of a novel phosphodiesterase 4 (PDE4) inhibitor ZL-n-91 in preparation of medicines for treating growth and metastasis of oral cancer. In-vitro cytology experiments and in-vivo zoology experiments show that the phosphodiesterase 4 inhibitor ZL-n-91 can significantly inhibit proliferation and migration of the oral cancer, reveals that the phosphodiesterase 4 inhibitor ZL-n-91 is expected to treat the oral cancer, and has good development and application prospects.

Provided herein are methods of reducing body weight in a subject in need thereof by administering to the subject compositions comprising a PDE10 inhibitor. Also disclosed are crystalline solid forms of the compound of Formula I and uses thereof : (I)

The instant invention relates to the use of a substance with phosphodiesterase-7 inhibitory activity (PDE7 inhibitor), such as spiro[[1,3]oxazolo[5,4f-]quinazoline-9,1′-cyclohexan)-7-one derivatives, as active ingredient in a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of different diseases, syndromes, disease states, or conditions associated with chronic fatigue, exhaustion and / or exertional intolerance using PDE7 inhibitors alone or in combination with other therapeutic agents.

The present invention relates to a dihydrothiopyranopyrimidine compound exhibiting phosphodiesterase-4 (PDE-4) inhibitory activity, and more specifically, to: a dihydrothiopyranopyrimidine compound exhibiting excellent PED-4B inhibitory activity, an optical isomer, stereoisomer, solvate, isotopic variant, or tautomer thereof, or a pharmaceutically acceptable salt thereof; and a use thereof in the prevention, amelioration, or treatment of diseases caused by PDE-4 activity.